SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
BrainCells and Organon to collaborate in discovery and development of CNS drugs
News | 10. 23. 2006
BrainCells
BrainCells Inc. (BCI) and Organon, the human health care business unit of Akzo Nobel (Nasdaq: AKZOY), today announced they will collaborate in the discovery and development of drugs for the treatment of central nervous system (CNS) disorders.
